196 related articles for article (PubMed ID: 9926629)
21. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer.
Nelson HD; Fu R; Griffin JC; Nygren P; Smith ME; Humphrey L
Ann Intern Med; 2009 Nov; 151(10):703-15, W-226-35. PubMed ID: 19920271
[TBL] [Abstract][Full Text] [Related]
22. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
[TBL] [Abstract][Full Text] [Related]
23. Risk versus Benefit of Chemoprevention among Raloxifene and Tamoxifen Users with a Family History of Breast Cancer.
Anderson C; Nichols HB; House M; Sandler DP
Cancer Prev Res (Phila); 2019 Nov; 12(11):801-808. PubMed ID: 31431499
[TBL] [Abstract][Full Text] [Related]
24. Current controversies in breast cancer management.
Morrow M; Jordan VC; Takei H; Gradishar WJ; Pierce LJ
Curr Probl Surg; 1999 Mar; 36(3):163-216. PubMed ID: 10089889
[No Abstract] [Full Text] [Related]
25. Tamoxifen, raloxifene findings unlikely to encourage genetic screening for breast cancer.
Dove A
Nat Med; 1998 Jun; 4(6):647. PubMed ID: 9623955
[No Abstract] [Full Text] [Related]
26. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
Freedman AN; Yu B; Gail MH; Costantino JP; Graubard BI; Vogel VG; Anderson GL; McCaskill-Stevens W
J Clin Oncol; 2011 Jun; 29(17):2327-33. PubMed ID: 21537036
[TBL] [Abstract][Full Text] [Related]
27. Risk-benefit profiles of women using tamoxifen for chemoprevention.
Nichols HB; DeRoo LA; Scharf DR; Sandler DP
J Natl Cancer Inst; 2015 Jan; 107(1):354. PubMed ID: 25475563
[TBL] [Abstract][Full Text] [Related]
28. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen.
Bergman L; Beelen ML; Gallee MP; Hollema H; Benraadt J; van Leeuwen FE
Lancet; 2000 Sep; 356(9233):881-7. PubMed ID: 11036892
[TBL] [Abstract][Full Text] [Related]
29. Use of raloxifene and tamoxifen by breast cancer risk level in a Medicare-eligible cohort.
Pinsky PF; Miller E; Heckman-Stoddard B; Minasian L
Am J Obstet Gynecol; 2018 Jun; 218(6):606.e1-606.e9. PubMed ID: 29630889
[TBL] [Abstract][Full Text] [Related]
30. Tamoxifen therapy--long-term results and complications.
Moore MP; Kinne DW
Adv Surg; 1996; 29():263-9. PubMed ID: 8720007
[No Abstract] [Full Text] [Related]
31. Tamoxifen, raloxifene, and the prevention of breast cancer.
Jordan VC; Morrow M
Endocr Rev; 1999 Jun; 20(3):253-78. PubMed ID: 10368771
[No Abstract] [Full Text] [Related]
32. Tamoxifen in cancer therapy: minireview.
Novotny L; Rauko P; Vachálková A; Peterson-Biggs M
Neoplasma; 2000; 47(1):3-7. PubMed ID: 10870680
[TBL] [Abstract][Full Text] [Related]
33. One step forward or one step back with tamoxifen?
Gelmon K
Lancet; 2000 Sep; 356(9233):868-9. PubMed ID: 11036885
[No Abstract] [Full Text] [Related]
34. Chemoprevention of breast cancer.
Brown PH; Lippman SM
Breast Cancer Res Treat; 2000 Jul; 62(1):1-17. PubMed ID: 10989982
[TBL] [Abstract][Full Text] [Related]
35. Tamoxifen. 'A big deal,' but a complex hand to play.
Marshall E
Science; 1998 Apr; 280(5361):196. PubMed ID: 9565527
[No Abstract] [Full Text] [Related]
36. Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow.
Jordan VC
J Natl Cancer Inst; 1998 Jul; 90(13):967-71. PubMed ID: 9665143
[No Abstract] [Full Text] [Related]
37. Chemoprevention of breast cancer by tamoxifen: risks and opportunities.
Smith LL; Brown K; Carthew P; Lim CK; Martin EA; Styles J; White IN
Crit Rev Toxicol; 2000 Sep; 30(5):571-94. PubMed ID: 11055836
[TBL] [Abstract][Full Text] [Related]
38. Exemestane for primary prevention of breast cancer in postmenopausal women.
Zhang Y; Simondsen K; Kolesar JM
Am J Health Syst Pharm; 2012 Aug; 69(16):1384-8. PubMed ID: 22855103
[TBL] [Abstract][Full Text] [Related]
39. Endometrial changes with chronic tamoxifen use.
Loret de Mola JR
Curr Opin Obstet Gynecol; 1997 Jun; 9(3):160-4. PubMed ID: 9263698
[TBL] [Abstract][Full Text] [Related]
40. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
Jordan VC; Gapstur S; Morrow M
J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]